Feb 06, 2023
Director/PDMR Shareholding
RNS Number : 0685P MaxCyte, Inc. 06 February 2023   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Exercise of options, PDMR dealing and Total Voting Rights   ROCKVILLE, MD , February 6, 2023  -   MaxCyte (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell   -   engineering company focused on
Read More →
Feb 02, 2023
Notice of Results
RNS Number : 7153O MaxCyte, Inc. 02 February 2023   MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences   ROCKVILLE, MD , February 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering
Read More →
Jan 30, 2023
Exercise of options and PDMR dealing
RNS Number : 2143O MaxCyte, Inc. 30 January 2023   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Exercise of options, PDMR dealing and Total Voting Rights   ROCKVILLE, MD , January 30, 2023  -   MaxCyte (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell   -   engineering company focused on
Read More →
Jan 04, 2023
Signing of Strategic Platform License
RNS Number : 5691L MaxCyte, Inc. 04 January 2023         MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs   MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell
Read More →